Current trial data suggest that many MCED tests demonstrate high specificity, often above 99% thereby reducing the likelihood of false positives ...
Carfilzomib prevented BCMA degradation, increased target density, and improved CAR T susceptibility by ~26%–28% in vitro, while enhancing xenograft antitumor activity without worsening T-cell ...
Hepta refractory multiple myeloma is marked by antigen loss, genomic complexity, and 12.8 month median survival in multi centre data.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results